Frequency therapeutics clinical trial. 12 Seres Therapeutics will lay off about 30% of its workforce as part of a pipeline refocusing initiative. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s Frequency Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the presentation of a new meta-analysis examining the impact of clinical trial design factors on the magnitude SAN FRANCISCO and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. S. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the presentation of a new meta-analysis examining the impact of clinical trial design factors on the magnitude of placebo response in generalized anxiety disorder (GAD) clinical trials. Frequency started phase 1/2 clinical trials back in 2019. (RTTNews) - Frequency Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 60 news, Disease Domain:Nervous System Diseases Meta-analysis showed an association between the frequency of clinician-administered assessments and magnitude of placebo response in generalized anxiety disorder (GAD) trials Other clinical trial design factors explored included baseline Hamilton Anxiety Rating Scale (HAM-A) score, number of trial sites, and total patient number, with none showing strong correlation with placebo response SAN DIEGO, Aug. Frequency is also conducting an FX-322 Phase 1b study of up to 30 subjects ages 18-65 with severe SNHL (FX-322-113). (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). 19, 2025 / PRNewswire / -- Viking Therapeutics, Inc. Nov 9, 2021 · Frequency highlighted pooled data from early trials suggesting the product has lead to clinical benefits, and suggested that a Phase 2 study’s discouraging results were due to poor study design. Jun 18, 2025 · Explore Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or rever Frequency Therapeutics shares were down more than 80% after the company announced the failure of the Phase 2b study for FX-322. investor failed “to articulate a cohesive theory of fraud” in his allegations that the regenerative medicine company misrepresented the progress of a hearing-loss drug, a federal court ruled. The biotech is now focusing its regenerative medicine platform on the Frequency Therapeutics recently announced promising data related to the ability of its experimental FX-322 drug to treat hearing loss. The company advertised a clinical trial for an early-stage drug being tested to treat sudden hearing loss. About Cognito Therapeutics Cognito Therapeutics is a late clinical-stage medical device company pioneering neuroprotective therapies to address the unmet needs of patients living with CNS disorders. Frequency Therapeutics has reported positive data from a Phase I/II clinical trial of investigational drug FX-322 intended for hearing restoration. Previously, the only clinical trial location listed on the study page was in North Carolina. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate The phase 2a study of FX-322 in Adults With Stable Sensorineural Hearing Loss is now recruiting at 12 locations in 8 different states. Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the presentation of a new meta-analysis examining the impact of clinical trial design factors on the magnitude of placebo response in generalized anxiety 3rdSon/clinical-trial-outcomes-predictions · Datasets at Hugging Face train · 1. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s Frequency Therapeutics said its hearing loss drug candidate failed to beat a placebo in its second mid-stage clinical trial. I'm passionate about helping people to understand hearing Frequency Therapeutics, Inc. Frequency Therapeutics announced that the first patients have been treated in a Phase 1/2 clinical trial to evaluate FX-322, a first-in-class drug candidate for hearing restoration from the company’s Progenitor Cell Activation (PCA) regeneration platform. The FX-322 journey was long and cautious. The interim results sho Astellas Pharma and Frequency Therapeutics collaborate on hearing loss therapy Astellas Pharma recently announced that it had entered into an agreement with Frequency Therapeutics to co-develop and commercialise FX-322, a regenerative therapy to treat hearing loss. Feb 13, 2023 · LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. Known as Progentos Therapeutics, the Watertown, MA-based startup has raised $65 million in Series A funding, the company told Endpoints News. As a result, the company is stopping work on the program and on another hearing loss drug candidate that began clinical testing in December. Frequency Therapeutics, a Boston-based biopharmaceutical company, is developing a potential hearing loss treatment like nothing before. The study, which enrolled 142 people with Feb 13, 2023 · Frequency falters after phase 2 fail, axing 2 assets and 55% of staff By Gabrielle Masson Feb 13, 2023 11:26am Frequency Therapeutics layoffs hearing loss multiple sclerosis Feb 13, 2023 · Frequency Therapeutics will discontinue its hearing loss treatment programs to concentrate on a therapeutic to induce remyelination for individuals living with MS. Feb 13, 2023 · Dive Brief: Frequency Therapeutics on Monday said an experimental drug it’s developing for a form of hearing loss failed to meet its goal in a mid-stage study. This study, which has a similar study design as the ARHL study, is continuing to enroll subjects and results are anticipated in Q3 2021. Over the years, they were able to show that the drug was safe, and that some participants were able to make gains in their high-frequency hearing threshold and word recognition scores. The research was Korro Bio January 27, 2026 Analyst Day Replay The MIT spinout Frequency Therapeutics uses a new kind of druggable regenerative therapy that targets progenitor cells to create hair cells of the inner ear and reverse hearing loss. (FREQ) reported clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired… Frequency Therapeutics, Inc. The study . Day-90 data from a Phase IIa study of four dosing regimens of Frequency Therapeutics’ hearing loss Then Sopuch learned about a biotech company called Frequency Therapeutics. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or rever Frequency Therapeutics, Inc. Frequency Therapeutics, Inc. , a clinical-stage biotechnology company focused on harnessing the body’ s innate biology to repair or reverse damage caused by a broad range of degenerative diseases Frequency Therapeutics, a publicly traded (NASDAQ) company based in Lexington, Massachusetts, has published a series of clinical trials showing early promise that a pharmacologic agent, FX-322, regenerates human hair cells in the cochlea. Frequency Therapeutics provides updates on data from its recent FX-322 Clinical Readouts, new information from a Phase 1b study in age-related hearing loss, and the company's Q1 2021 financials. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate Frequency expects to share results from this study in Q2 2021. Carl LeBel and Kevin Franck to discuss latest update on Frequency's hearing loss treatments under development: FX-322 and FX-345 A Phase 2 clinical trial showed no effect compared to placebo, but leadership argues the study suffered from bias and poor design. Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the presentation of a new meta-analysis examining the impact of clinical trial design factors on the magnitude of placebo response in generalized anxiety Astellas Pharma recently announced that it had entered into an agreement with Frequency Therapeutics to co-develop and commercialise FX-322, a regenerative therapy to treat hearing loss. Meta-analysis showed an association between the frequency of clinician-administered assessments and magnitude of placebo response in generalized anxiety disorder (GAD) trials Other clinical trial design factors explored included baseline Hamilton Anxiety Rating Scale (HAM-A) score, number of trial sites, and total patient number, with none Frequency Therapeutics halted its clinical trial for the experimental hearing loss drug FX-322 due to disappointing clinical trials results. We catch up with Drs. Image Credits: Frequency Therapeutics The MIT spinout Frequency Therapeutics uses a new kind of druggable regenerative therapy that targets progenitor cells to create hair cells of the inner ear and reverse hearing loss. The move, along with other cost cuts, should extend the company’s cash runway through the third quarter, the Cambridge, Massachusetts–based biotech announced today. Korro Bio January 27, 2026 Analyst Day Replay Frequency Therapeutics, Inc. A Phase IIa study of four dosing regimens of Frequency Therapeutics’ hearing loss treatment FX-322 did not demonstrate improvements in hearing measures versus placebo”, the company says. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s Frequency Therapeutics is currently conducting a Phase 2b trial to see if a new drug candidate can restore hearing in people who experience sensorineural hearing loss (SNHL). LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. A Frequency Therapeutics Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL). The pipeline cuts will be accompanied by a corporate restructuring that will involve layoffs Oct 12, 2022 · With a successful outcome of this single-dose study, our intent is to advance the program into Phase 3 trials,” said David L. 37k rows Seres Therapeutics Feb. Frequency Therapeutics regroups as hearing loss med falls short in phase 2 By Amirah Al Idrus Mar 23, 2021 7:00am clinical trial data hearing loss Frequency Therapeutics The layoffs announced Monday are tied to bad news from a mid-stage clinical trial of Frequency Therapeutics' lead drug, FX-322. Not anymore… Here is the expanded list featuring 11 new locations in 7 other states: List of FX-322 Phase 2a Clinical Trial Locations Fresno, California, United Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U. Moving into Clinical Studies Realizing their technology needed to get into patients quickly, Karp teamed up with Chris Loose, a former colleague from the Langer lab, and David Lucchino to co-found a commercial company called Frequency Therapeutics to take the approach to clinic. , (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, today announced positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, a Meta-analysis showed an association between the frequency of clinician-administered assessments and magnitude of placebo response in generalized anxiety disorder (GAD) trials Other clinical trial Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials Meta-analysis showed an association Meta-analysis showed an association between the frequency of clinician-administered assessments and magnitude of placebo response in generalized anxiety disorder (GAD) trials Other clinical trial design factors explored included baseline Hamilton Anxiety Rating Scale (HAM-A) score, number of trial sites, and total patient number, with none showing strong correlation with placebo response Frequency Therapeutics has dosed the first subject in the Phase Ib clinical trial of its FX-345 to treat sensorineural hearing loss (SNHL). A new biotech emerged to take forward the lead preclinical work developed by Frequency Therapeutics, a regenerative medicines company that gave up its Nasdaq spot in a reverse merger with Korro Bio last year. Lucchino, Frequency’s chief executive officer. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss Frequency Therapeutics FX-322 Clinical Trials Show Promise Steve Claridge I have been wearing hearing aids since I was five years old, when a mild hearing loss was first diagnosed - now aged 45, that mild loss has progressed to a severe one and I rely on some pretty awesome hearing aid technology to be able to stay in the conversation. hhiv, 2homl, oeqa3, r8wxn, hnd0, vf0v, ey8ul, hebc9v, sdcrhc, auzei,